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DISCUSSION
Dr Dennis Fry (Iowa City, Ia). I just have two questions.
First, you said that you do stress tests in all your patients. Does that
change your approach in the 35% of symptomatic patients? For
instance, do they go to coronary bypass or do they go to angio-
plasty and stenting before undergoing carotid endarterectomy?
And then my second question, which is more of a comment, is that
there was an article recently by Kim et al in Circulation in 2002,
and they stated there was a sixfold increase in mortality for non-
Q-wave MIs, and it sounded like you were suggesting that non-
Q-wave MIs didn’t matter that much.
Dr Geza Mozes. Regarding the first question, one of the
inclusion criteria in the SAPPHIRE trial was having a preoperative
positive stress test; therefore, in this study, in the high-risk group,
we included only those patients with a positive stress test who did
not have an intervention between the positive stress test and the
carotid endarterectomy. If the cardiac stress test is highly positive,
then our patients routinely undergo percutaneous coronary revas-
cularization.
The other question recalls a very, very important issue, and
comes up repeatedly in this discussion. One thing we have to ask at
first is, Do you think that having a subendocardial MI is the cause
of a future death, or is it just an indicator, a sort of stress test, that
points to a population with poor cardiac prognosis?
Dr Iraklis Pipinos (Omaha, Neb). This is certainly important
data that will influence our daily decision-making. The SAPPHIRE
trial reported a significantly higher non-Q-wave MI rate in their
patients having carotid endarterectomies. Of interest, it was that
higher rate, around 5% to 6%, that made their 30-day combined
death, stroke, and MI rates significantly worse in the endarterec-
tomy patients compared with the patients receiving angioplasty
and stenting. What do you think accounts for the difference
between their non-Q-wave MI rate and the one you observed in
your series?
Dr Mozes. It is a good question. First of all, one should
assume in this retrospective study that we may have overlooked a
few minor events. However, I mentioned during the talk that it is
our policy to check troponin after every single endarterectomy;
therefore our sensitivity may have been quite reasonable. I don’t
have a good explanation why our results are better. We follow usual
rules by applying aggressive -blockade and extensive preoperative
cardiac workup. Also, when you take numbers from two different
studies it is very difficult to compare them face to face. The
SAPPHIRE trial was a relatively small study, so what we are seeing
here may be just a statistical variation.
Dr Donald Jacobs (St Louis, Mo). I would take a different
bent on your data, to say that you just have reaffirmed the findings
of the SAPPHIRE trial, that is, these patients do have increased risk
for non-Q-wave MI. Whether that is significant or not could be
debated. Also, the risk of stroke, although statistically not different,
may be a number that would be significant in larger numbers, a
larger study. I think that again they are not that different, the
high-risk stroke rate in your hands and the ones that were in the
SAPPHIRE trial. I’m not sure I would take the same approach that
shows that these patients are not at high risk. But indeed there is a
difference, and the results are not that greatly different from the
SAPPHIRE data. I wonder what your comments are on that.
Dr Mozes. I agree that there are several different ways to look
at the same set of data. The question is, Where do you want to put
the emphasis? I think that we should emphasize that SAPPHIRE-
eligible status should not necessarily be an indication for carotid
artery stenting. What we suggest is that it would not be correct to
submit 42% of the whole population to carotid artery stenting,
based on the preliminary data of the SAPPHIRE trial. On the other
hand, I agree that if we look at the symptomatic high-risk patients,
which is a much smaller population, about 15% of the entire
population, then you can make an argument that those patients, at
least in the short run, will do better with stenting. Indeed, that
pretty much describes our practice; in addition to the patients with
local risks, the patients who are symptomatic and have very high
medical risk are those to whom we recommend stenting. Again, if
you put all of these numbers together, that will be about 15% of the
population, and not 42%. This is the point of this study.
Dr Timothy Sullivan. I would just like to make a brief
comment, as the senior author of the paper, that the idea is not to
condemn carotid angioplasty and stenting. Simply stated, perhaps
we need to raise the bar a little bit in terms of comparing angio-
plasty and stenting in high-risk patients with endarterectomy in
high-risk patients. The idea is not that angioplasty and stenting has
to meet a standard of 6% risk for stroke and death in symptomatic
patients, and 2% or 3% in asymptomatic patients, but in fact the bar
is substantially higher than that. Carotid endarterectomy remains
the gold standard for most patients, whether high or low risk.
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In an ongoing effort to refine indications for carotid endarter-
ectomy (CEA), multiple investigators have attempted to define
“high-risk” subgroups in which the outcomes of CEA are worse
than generally expected. The hypothesis has been that carotid
artery stenting (CAS) would be preferable in such patients. The
SAPPHIRE trial, completed in 2002 but not yet published, is an
effort to test this hypothesis in a prospective randomized trial.
Results, presented in abstract form, are sobering for advocates of
CEA and CAS alike.
In this issue of the JVS, Mozes et al present the latest of several
single-institution retrospective reviews in which patients were di-
vided into normal- and high-risk categories on the basis of criteria
used in “high-risk” trials such as SAPPHIRE.1-3 Their results, like
those of other surgical series, fail to show different outcomes
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between patient groups defined as high-risk and normal-risk. How
can these results be reconciled with SAPPHIRE? Until details of
study design and outcome data for SAPPHIRE are published in
full, one can only speculate. Certainly, prospective randomized
trials can be expected to identify more adverse events than retro-
spective reviews. In the current study, routine cardiac enzymes
were evaluated postoperatively, making significant underestima-
tion of the major area of difference in SAPPHIRE—cardiac end
points—unlikely. The similarity of outcomes between the current
study and prior single-institution reports suggests that other fac-
tors should also be considered.
Single center studies such as this one from the Mayo clinic
have the advantage of increased homogeneity in patient selection,
preoperative evaluation and intraoperative and postoperative man-
agement that are difficult to achieve in multicentered studies.
Preoperative cardiac evaluation and uniform operative and anes-
thetic management, including antiplatelet therapy and  blockade,
are all more likely to be standard in a single-center study. Several of
these features were highlighted in the Mayo Clinic series. The
authors noted their preference for nonoperative management of
patients with very high cardiac risk and asymptomatic carotid
stenosis, frequent use of preoperative cardiac screening, and rou-
tine use of perioperative -adrenergic blockade in their patients. It
is likely that these factors, along with meticulous surgical tech-
nique, played an important role in their uniformly excellent results.
Such a level of conformity is more difficult to achieve in multicen-
tered studies. Variation in patient selection may exist in multicen-
tered studies, even with established inclusion and exclusion crite-
ria. Details of preoperative evaluation and perioperative
management are likely to vary most markedly in the surgical arm of
multicentered studies. It will be important to know how closely
factors such as preoperative cardiac screening, periprocedural use
of heparin and antiplatelet agents,  blockers, and intensive care
unit monitoring were controlled in both the stenting and surgical
arms of SAPPHIRE before the significance of its results can be
analyzed.
A consensus is emerging that there is a subgroup of high-risk
patients in whom CEA will have a more adverse outcome. This
group is certainly more narrowly defined than high-risk stenting
trials have maintained, although it is probably larger than most
surgeons realize. For the present, CAS outside clinical trials should
be restricted to a truly high-risk CEA group. Based on the previ-
ously reported surgical series reported,1-3 as well as this one, this
group includes patients with a hostile neck, recurrent stenosis, and
nonreconstructable coronary disease. The number of such patients
is small, and will likely be much smaller if patients with asymptom-
atic carotid stenosis are considered for noninterventional manage-
ment. It is important that all who contemplate intervention for
patients with carotid stenosis remember that both CAS and CEA
are procedures with real and dramatic complications. This is par-
ticularly relevant in the neurologically symptom-free patients. That
is the real message of the SAPPHIRE data as presented to date.
“Results are everything.”4 Mozes et al have shown that careful
patient selection, excellent operative techniques, and careful peri-
operative management can produce outstanding results with CEA
in both “normal” and “high-risk” patients. However, neither CEA
nor CAS is appropriate for everyone with carotid bifurcation
stenosis. It is incumbent on vascular surgeons to learn both tech-
niques, so they can select the proper intervention, or no interven-
tion at all, in the patient’s best interest.
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